Subsequent Events

12 Months Ended

Sep. 30, 2018

Subsequent Events [Abstract]

Subsequent Events

23.    Subsequent Events

Acquisition

On September 26, 2018, the Company entered into a definitive agreement to acquire GENEWIZ, a leading provider of genomic services, based in New Jersey with operations throughout the United States, Asia, and Europe, for $450.0 million in cash, subject to customary adjustments. The Company completed this acquisition on November 15, 2018. 

Term Loan Modification

On November 15, 2018, in connection with the Company’s acquisition of GENEWIZ, the Company entered into an amendment of the existing term loan agreement which increased its outstanding principal balance to $546.0 million. The Company used the proceeds from this extended loan to pay a portion of the purchase price for GENEWIZ.

Dividend

On November 6, 2018, the Company’s Board of Directors declared a cash dividend of $0.10 per share payable on December 20, 2018 to common stockholders of record as of December 7, 2018. Dividends are declared at the discretion of the Company’s Board of Directors and depend on the Company’s actual cash flow from operations, its financial condition and capital requirements, as well as any other factors the Company’s Board of Directors may consider relevant. Future dividend declarations, as well as the record and payment dates for such dividends, will be determined by the Company’s Board of Directors on a quarterly basis.